10 completed, 4 recruiting, 4 unknown, 2 terminated. 5 Not applicable, 5 Phase 2, 4 Phase 1, 4 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Recruiting 2, Unknown 1 |
| Phase 2 | 5 | Recruiting 2, Unknown 2, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 4 | 2 | Completed 2 |
Follow Etodolac: new trials by email Literature Review of Etodolac trials Research Report on Etodolac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis Propionic acid deriaves, acetic acid derivatives, oxicam derivatives - Frozen Shoulder, Adhesive Capsulitis | Not applicable | Recruiting | Konya Beyhekim Training and Research Hospital | 120 | 2026-04-01 | 2026-05-14 |
| Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor), Placebo (Matching for Propranolol & Etodolac) - Ovarian Cancer, Ovarian Cancer Metastatic Recurrent | Phase 2 | Recruiting | Tel-Aviv Sourasky Medical Center | 60 | 2025-03-12 | 2025-07-11 |
| Lornoxicam Versus Etodolac After Third Molar Surgery Lornoxicam 8 Mg Oral Tablet - Pain, Acute, Edema | Phase 4 | Completed | Kutahya Health Sciences University | 20 | 2022-07-20 | 2023-01-11 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) Mind-body resilience training, Music therapy, Propranolol - Ovarian Cancer, Ovarian Carcinoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 35 | 2022-06-17 | 2026-07-01 |
| Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction Fixed Dose Combination, Etodolac, Cyclobenzaprine - Pain, Acute | Phase 3 | Terminated | Apsen Farmaceutica S.A. | 140 | 2020-10-05 | 2026-09-09 |
| Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery Propranolol and etodolac, Placebo - Pancreatic Neoplasms | Phase 2 | Unknown | Assaf-Harofeh Medical Center | 210 | 2019-11-20 | 2019-11-20 |
| Colorectal Metastasis Prevention International Trial 2 Propranolol and etodolac, Placebo - Colorectal Neoplasms | Phase 2 | Recruiting | Assaf-Harofeh Medical Center | 200 | 2019-02-28 | 2019-04-18 |
| Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters Etodolac 400 MG, Thiocolchicoside - Occlusion, Quality of Life | Not applicable | Completed | Yuzuncu Yil University | 60 | 2018-12-01 | 2022-03-02 |
| Etodolac and Post-bleaching Sensitivity Etodolac, Placebo - Medicaments Substances in Therapeutic Use | Phase 4 | Completed | Flavia Pardo Salata Nahsan | 50 | 2014-11-01 | 2016-08-29 |
| Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery Propranolol, etodolac - Primary Operable Breast Cancer | Not applicable | Unknown | Kaplan Medical Center | 32 | 2014-06-01 | 2014-07-01 |
| Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer VT-122, Placebo - Prostatic Neoplasms | Phase 2 | Terminated | Vicus Therapeutics | 35 | 2013-06-01 | 2018-04-26 |
| Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition Etodolac Capsules USP 300 mg, Etodolac - Healthy | Phase 1 | Completed | IPCA Laboratories Ltd. | 36 | 2012-10-01 | 2012-12-13 |
| Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition Etodolac Capsules USP 300 mg, Etodolac - Fasting | Phase 1 | Completed | IPCA Laboratories Ltd. | 36 | 2012-10-01 | 2012-12-11 |
| The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT Instruction on analgesic use for pain relief (acetaminophen and NSAIDs), Neuromuscular exercise - Osteoarthritis, Knee | Not applicable | Completed | University of Southern Denmark | 93 | 2012-08-01 | 2016-08-03 |
| Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition Etodolac Tablets USP 500mg, Etodolac Tablets USP 500 mg - Fed | Phase 1 | Completed | IPCA Laboratories Ltd. | 36 | 2012-05-01 | 2012-12-03 |
| Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition Etodolac Tablets USP 500mg, Etodolac Tablets USP 500 mg - Fasting | Phase 1 | Completed | IPCA Laboratories Ltd. | 36 | 2012-05-01 | 2012-12-03 |
| Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) Sorafenib, VT-122 (propranolol plus etodolac), Placebo - HCC | Phase 2 | Unknown | Vicus Therapeutics | 20 | 2010-12-01 | 2015-12-09 |
| MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains MRX-7EAT, Placebo, Lidocaine - Ankle Sprains | Phase 3 | Completed | MEDRx USA, Inc. | 600 | 2010-09-01 | 2018-01-17 |
| A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients YM177, etodolac, Placebo - Post Operative Pain | Phase 3 | Completed | Astellas Pharma Inc | 616 | 2010-02-01 | 2014-10-15 |
| β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence Propranolol and Etodolac - Colorectal Neoplasms | Phase 3 | Unknown | Sheba Medical Center | 400 | 2010-01-01 | 2011-07-12 |
Acute Pain (2) · Colorectal Neoplasms (2) · Fasting (2) · Lecithin Cholesterol Acyltransferase Deficiency (2) · Ovarian Neoplasms (2) · Agnosia (1) · Ankle Injuries (1) · Bites and Stings (1) · Breast Neoplasms (1) · Bursitis (1) · Carcinoma, Ovarian Epithelial (1) · Edema (1) · Fallopian Tube Neoplasms (1) · Motor Activity (1) · Neoplasms (1)
IPCA Laboratories Ltd. (4) · Assaf-Harofeh Medical Center (2) · Vicus Therapeutics (2) · Apsen Farmaceutica S.A. (1) · Astellas Pharma Inc (1) · Flavia Pardo Salata Nahsan (1) · Kaplan Medical Center (1) · Konya Beyhekim Training and Research Hospital (1) · Kutahya Health Sciences University (1) · MEDRx USA, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · Sheba Medical Center (1) · Tel-Aviv Sourasky Medical Center (1) · University of Southern Denmark (1) · Yuzuncu Yil University (1)
Israel (5) · India (4) · United States (4) · Turkey (Türkiye) (3) · Brazil (1) · Denmark (1) · Japan (1)
Dr. Hardik Dave, M.B.B.S. (4) · Oded Zmora, MD (2) · Anna Blecher, Dr. (1) · Brian Clausen, PT, M.Sc. (1) · Eran Sharon, MD (1) · Ewa M. Roos, Professor (1) · Flavia Pardo Salata Nahsan (1) · Martine Francis (1) · Moshe Shabtai, MD (1) · Nadav Michaan, Prof. (1) · Shamgar Ben-Eliyahu, PhD (1) · Shamgar Ben-Eliyahu, Prof. (1) · Tanir M Allweis, MD (1)
PMID 42088573, PMID 24050955, PMID 25399048, PMID 27836677, PMID 28490464, PMID 29107059, PMID 29800703
R21CA291683 (1)